Patents Examined by San Ming R. Hui
  • Allosteric activators for treatment of phenylketonuria
    Patent number: 10426751
    Abstract: A method of restoring activity in phenylalanine hydroxylase is provided. The method comprises exposing the phenylalanine hydroxylase to shikimic acid, a functionally equivalent analog thereof, a pharmaceutically acceptable salt of shikimic acid or analog thereof, or combinations thereof.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: October 1, 2019
    Assignee: McMaster University
    Inventor: Philip Britz-McKibbin
  • Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
    Patent number: 10413561
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: September 17, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Enkephalin-influencing composition and method
    Patent number: 10413523
    Abstract: A composition which includes Phenylalanine, Serine, Glutamine and GABA (?-aminobutyric acid). The composition contains the essential amino acids Phenylalanine; Glutamine; the non-essential amino acid Serine; and GABA (?-aminobutyric acid) in concentrations effective to influence or modulate the neurotransmitter pentapeptide enkephalin. The composition may further comprise tetrahydrocannabinol (THC).
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: September 17, 2019
    Assignee: BIOADATP, LLC
    Inventor: Kevin Meehan
  • Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
    Patent number: 10406130
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing sdLDL oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: September 10, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Richard Preston Mason
  • Levothyroxine liquid formulations
    Patent number: 10398669
    Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: September 3, 2019
    Assignee: Fresenius Kabi USA, LLC
    Inventors: Arunya Usayapant, Basma M. Ibrahim
  • Compositions and methods for the treatment of neurodegenerative and other diseases
    Patent number: 10398713
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: September 3, 2019
    Assignee: Glialogix, Inc.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Reduced dose intravenous acetaminophen
    Patent number: 10383834
    Abstract: Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 20, 2019
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Mike Allan Royal, James Bradley Breitmeyer
  • Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
    Patent number: 10378068
    Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: August 13, 2019
    Assignees: Loxo Oncology, Inc., Array BioPharma, Inc.
    Inventors: Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
  • Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
    Patent number: 10370727
    Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: August 6, 2019
    Assignees: Loxo Oncology, Inc., Array BioPharma, Inc.
    Inventors: Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
  • Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
    Patent number: 10369152
    Abstract: Provided herein are methods and compositions for the treatment and/or prevention of abnormal bone formation in a soft tissue. In certain embodiments, the methods and compositions treat and/or prevent a disease or disorder comprising abnormal bone formation in soft tissue. Exemplary diseases or disorders that can be treated with the methods and compositions described herein include, but are not limited to, heterotopic ossification diseases such as fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: August 6, 2019
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Paul B. Yu, Jana Bagarova, Devaveena Dey
  • Methods and assays relating to sepiapterin reductase inhibition
    Patent number: 10365267
    Abstract: Described herein are methods and assays relating to the inhibition of sepiapterin reductase and measuring said inhibition by measuring the level of sepiapterin. In some embodiments, the methods can further relate to treating a subject with BH4 and/or BH2.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 30, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Clifford J. Woolf, Alexandra S. Latini, Nick A. Andrews, Alban Latremoliere, Michael Costigan
  • Neridronic acid for treating complex regional pain syndrome
    Patent number: 10350227
    Abstract: Neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: July 16, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Topical pharmaceutical composition of acitretin
    Patent number: 10342774
    Abstract: The present invention relates to a topical pharmaceutical composition comprising acitretin and a process for its preparation. It also relates to a method of treating skin disorders by administering said topical pharmaceutical composition.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: July 9, 2019
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Rathinasabapathy Venkateshwaran, Vikas Jain, Vaibhav Dubey, Sumit Madan, Vinod Kumar Arora, Rajesh Rao
  • Composition and methods for the treatment of CaMKK2-mediated disorders
    Patent number: 10336750
    Abstract: The present disclosure provides compositions and methods for treating ocular disorders in mammals especially in and not limited to humans and mice. The present disclosure further provides methods of treating cancer and appetite suppression using the compositions which are novel small molecule inhibitors of CaMKK2. In addition, these derived compositions can regulate non-ocular disorders, such as cancer and appetite suppression by modulating and inhibiting CaMKK2 and the regulation of the macrophage mediated diseases.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 2, 2019
    Assignee: Duke University
    Inventors: Scott W. Cousins, David M. Gooden, Priyatham S. Mettu
  • Anti-methanogenic compositions and uses thereof
    Patent number: 10328151
    Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: June 25, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
  • Methods for treating B cell proliferative disorders
    Patent number: 10314842
    Abstract: Described herein are methods for treating B cell proliferative disorders, in an individual in need thereof. The methods include administering to an individual in need thereof a Btk inhibitor (e.g., ibrutinib), in combination with a CDK4 inhibitor (e.g., palbociclib).
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: June 11, 2019
    Assignee: Cornell University
    Inventors: Selina Chen-Kiang, Maurizio Di Liberto
  • Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
    Patent number: 10314848
    Abstract: The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: June 11, 2019
    Assignee: EB IP LYBRIDOS B.V.
    Inventors: Jan Johan Adriaan Tuiten, Johannes Martinus Maria Bloemers, Robertus Petrus Johannes De Lange
  • KATP antagonists (glibenglamid) for use for promoting growth and/or treating hyperglycaemia of a premature infant
    Patent number: 10307430
    Abstract: The present invention relates to pharmaceutical compositions comprising an ATP-sensitive potassium (K ATP) channel antagonist (e.g., sulfonylureas, meglitinides) and methods for treating hyperglycaemia and/or promoting growth of a premature and/or small for gestational age infant.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: June 4, 2019
    Assignee: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Michel Polak, Marianne Berdugo Polak
  • Oral biofilm inhibitor
    Patent number: 10307342
    Abstract: There is provided an oral biofilm inhibitor having an exceptional inhibitory effect on oral biofilm formation. It is an oral biofilm inhibitor comprising a curable composition containing an antimicrobial agent, wherein a compressive strength of a cured product formed by curing the composition is 150 MPa or less, and a content of the antimicrobial agent is 0.001 to 3% by weight. An oral biofilm inhibitor thus obtained is used for inhibiting biofilm formation in an oral cavity by applying a curable composition containing an antimicrobial agent to a dental defect site for allowing the composition to cure at the dental defect site, and then disintegrating the cured composition.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: June 4, 2019
    Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Kazuhiro Omori, Takashi Ito, Shogo Takashiba, Masao Irie
  • Pharmaceutical compositions
    Patent number: 10300046
    Abstract: The present invention relates to pharmaceutical compositions useful for administration for treating, preventing, or reducing the risk of microbial infections.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: May 28, 2019
    Assignee: MELINTA SUBSIDIARY CORP.
    Inventor: Danping Li